Twist Bioscience director tax sale of 2,184 shares

Twist Bioscience director Robert Chess reported a small tax-related share sale.

Rhea-AI Filing Summary

Twist Bioscience director Robert Chess reported a small tax-related share sale. On February 13, 2026, 2,184 shares of Twist Bioscience common stock were sold at $48.261 per share to cover tax liabilities arising from the vesting of restricted stock units, pursuant to a prior election rather than a discretionary trade. Following this transaction, Chess directly held 21,084 common shares. He also indirectly held 42,528 common shares through the Chess 1997 Trust, where he and his spouse serve as the sole trustees and beneficiaries.

Insider Trade Summary

Net Seller: 2,184 shares

Net Sell 2 txns

Insider CHESS ROBERT

Role Director

Sold 2,184 shs ($105K)

Type	Security	Shares	Price	Value
Sale	Common Stock	2,184	$48.261	$105K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 21,084 shares (Direct); Common Stock — 42,528 shares (Indirect, By the Chess 1997 Trust)

Footnotes (2)

1. F1. Represents the number of shares sold by the Reporting Person to cover tax liability in connection with the vesting of Restricted Stock Units. This "sell to cover" transaction was made pursuant to a prior election by the Reporting Person and does not represent a discretionary trade by the Reporting Person.
2. F2. The Reporting Person and his spouse are the sole trustees and the sole beneficiaries of the Chess 1997 Trust.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Twist Bioscience (TWST) director Robert Chess report?

Robert Chess reported a sale of 2,184 Twist Bioscience common shares. The shares were sold on February 13, 2026 at $48.261 per share to cover tax liabilities from vesting restricted stock units under a prior election.

Was the Robert Chess share sale in Twist Bioscience (TWST) a discretionary trade?

No, the sale was not a discretionary trade by Robert Chess. The 2,184 shares were sold under a pre-arranged “sell to cover” election to satisfy tax liabilities from restricted stock unit vesting, as disclosed in the footnotes.

How many Twist Bioscience (TWST) shares does Robert Chess hold after the reported transaction?

After the transaction, Robert Chess directly held 21,084 Twist Bioscience common shares. In addition, 42,528 common shares were held indirectly through the Chess 1997 Trust, where he and his spouse are sole trustees and beneficiaries.

At what price were the Twist Bioscience (TWST) shares sold in Robert Chess’s Form 4 filing?

The 2,184 Twist Bioscience common shares were sold at $48.261 per share. This sale occurred on February 13, 2026 and was executed to cover tax liabilities from the vesting of restricted stock units, according to the disclosure.

What is the Chess 1997 Trust mentioned in the Twist Bioscience (TWST) Form 4?

The Chess 1997 Trust is an entity holding Twist Bioscience shares for Robert Chess and his spouse. They are the sole trustees and sole beneficiaries of the trust, which holds 42,528 common shares indirectly attributed in the Form 4.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/18/2026 - 04:05 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

X

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

CHESS ROBERT

(Last) (First) (Middle)

C/O TWIST BIOSCIENCE CORPORATION

681 GATEWAY BLVD.

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Twist Bioscience Corp [ TWST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/13/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/13/2026		S		2,184(1)	D	$48.261	21,084	D
Common Stock								42,528	I	By the Chess 1997 Trust(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the number of shares sold by the Reporting Person to cover tax liability in connection with the vesting of Restricted Stock Units. This "sell to cover" transaction was made pursuant to a prior election by the Reporting Person and does not represent a discretionary trade by the Reporting Person.

2. The Reporting Person and his spouse are the sole trustees and the sole beneficiaries of the Chess 1997 Trust.

Remarks:

	/s/ Kendra Fox, as Attorney-in-Fact for Robert Chess	02/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.